Rejuran Skinbooster 3+3: A Professional Guide to FDA, CE & Global Market Status

Rejuran Skinbooster 3+3 is manufactured by Pharma Research in South Korea, a prominent player in polynucleotide (PN) based medical aesthetics. The product's primary regulatory standing is based on its country of origin. It holds approval from the Korean Ministry of Food and Drug Safety (MFDS), often referred to as the KFDA.

Furthermore, Pharma Research operates under Good Manufacturing Practice (GMP) certification. This is a critical quality assurance standard that ensures products are consistently produced and controlled according to international quality standards. For buyers, KFDA approval and GMP certification are the foundational documents confirming the product's legitimacy and manufacturing quality at its source. Many suppliers can also provide ISO certification documents for the manufacturing facility, which pertains to quality management systems.

The most direct answer to the question of Rejuran Skinbooster FDA approval is that it is not an FDA-approved medical device for sale or use within the United States. The U.S. Food and Drug Administration has its own stringent review process for Class III medical devices, which includes most injectable aesthetic products. Rejuran has not completed this process.

For clinics and practitioners in the USA, this means the product cannot be legally marketed, sold, or administered. Importing it for professional use would fall outside of federal regulations. This is a common situation for many popular Korean injectables and differs significantly from the status of products like Sculptra (2 vials) or Radiesse 1.5, which have established FDA approvals.

The situation in the European Economic Area (EEA) and the post-Brexit UK is more complex. As of this writing, Rejuran Skinbooster 3+3 does not appear to hold a formal CE mark as an injectable medical device. This is a critical distinction for clinics operating within the EU, as the CE mark is mandatory for medical devices to be legally placed on the market.

Some Korean products are marketed in Europe under a different classification, or sold without a medical device CE mark, placing the compliance burden on the importing clinic. Professionals in the EU and UK must conduct thorough due diligence and verify the specific legal requirements for administering such products in their jurisdiction. The regulatory framework for these products is distinct from other product categories; for a detailed look at another Korean product's status, see the Lipo Lab V-Line: A Professional Guide to Regulatory & Market status.

Rejuran enjoys significant popularity in markets outside of the US and EU. In many Gulf Cooperation Council (GCC), Latin American (LATAM), and Asia-Pacific (APAC) countries, the regulatory pathways can be different. Some national health authorities in these regions may accept KFDA approval and GMP certification as sufficient for registration and import.

For example, in markets like Vietnam, Thailand, and the UAE, Rejuran is widely available through official distribution channels. However, each country has its own import regulations. Distributors and clinic owners in these regions should confirm the product's registration status with their local health ministry before stocking it. A reliable supplier should be able to provide documentation relevant to the specific destination market. The entire Skinbooster / biostimulator catalog contains products with varying levels of approval across these diverse regions.

Given its differing regulatory status worldwide, Rejuran is often a target for parallel importation and unauthorized distribution. Parallel imports are products sourced from one market and sold in another without the manufacturer's permission. While not always illegal, this practice introduces significant risks regarding product authenticity, storage conditions, and traceability.

Unverified suppliers may offer attractive pricing but often cannot provide a clear chain of custody. This can lead to clinics unknowingly acquiring counterfeit products or genuine products that have been improperly stored, compromising their integrity. When evaluating suppliers, procurement managers must prioritize transparency and documentation over price alone. Understanding the sourcing complexities of different products is key; for instance, the dynamics differ from those outlined in our Coretox 200 Units: A Professional Guide to Sourcing Amid Med.